TruScreen says covid-19 hit short-term

TruScreen says covid-19 hit short-term
Staff reporters
Cervical cancer screening technology company TruScreen said its operational loss after tax will be around $2.5 million in the year to March 31, narrower than its loss of $3.4 million in the prior year.Covid-19 has led to a decline in product revenue of around $1.38 million versus revenue of $1.86 million in the prior year, it said.The outbreak slowed the device roll-out in China but “China is now on a progressive lifting of restrictions and is on a gradual reinstatement of gynaecological clinics with sales volumes expected to recover by June 20...